Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02027272 · ClinicalTrials.gov registry record · NA
Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):
A NA study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT02027272 is a NA study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT02027272, a NA study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a double blinded, placebo-controlled trial to determine if IV dexamethasone more quickly than placebo assists resolution of Posterior Reversible Encephalopathy Syndrome (PRES) encountered in eclamptic patients. All patients regardless of assignment to placebo or steroid will receive standard therapy to include magnesium sulfate, blood pressure medications and diuretics. We hypothesize that the addition of dexamethasone to standard therapy will accelerate CNS recovery more quickly than standard management without dexamethasone.
Interventions
- DRUG Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02027272
The ClinicalTrials.gov registry entry for NCT02027272 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone is the first listed.
NCT02027272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02027272 about?
NCT02027272 is a clinical study titled "Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):". This is a double blinded, placebo-controlled trial to determine if IV dexamethasone more quickly than placebo assists resolution of Posterior Reversible Encephalopathy Syndrome (PRES) encountered in eclamptic patients. All patients regardless of assignment to placebo or steroid will receive standard...
What is the current status of trial NCT02027272?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2012-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT02027272?
The interventions under investigation include: Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT02027272?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.